domagrozumab (PF-06252616) / Pfizer  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
domagrozumab (PF-06252616) / Pfizer
NCT02310763 / 2014-002072-92: A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy

Terminated
2
121
Europe, Canada, Japan, US, RoW
PF-06252616, Placebo
Pfizer
Duchenne Muscular Dystrophy
04/18
11/18
NCT02907619 / 2016-001615-21: An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy

Terminated
2
59
Europe, Canada, Japan, US
PF-06252616
Pfizer
Duchenne Muscular Dystrophy
11/18
11/18
NCT02841267: A Trial of PF-06252616 in Ambulatory Participants With LGMD2I

Completed
1b/2
19
US
PF 06252616
Kathryn Wagner, Pfizer
LGMD2I
01/19
01/19

Download Options